B. Riley Comments on Geron’s Q1 Earnings (NASDAQ:GERN)

Geron Co. (NASDAQ:GERN) – Stock analysts at B. Riley issued their Q1 2025 EPS estimates for Geron in a research report issued on Wednesday, February 26th. B. Riley analyst K. Patel forecasts that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. B. Riley currently has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at ($0.02) EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $47.54 million during the quarter, compared to the consensus estimate of $45.29 million.

A number of other research firms also recently weighed in on GERN. Barclays reissued an “overweight” rating and set a $4.00 target price (down previously from $9.00) on shares of Geron in a report on Thursday. Needham & Company LLC dropped their price target on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. Stifel Nicolaus decreased their target price on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, Scotiabank decreased their target price on Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Geron has an average rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Trading Up 1.1 %

Shares of Geron stock opened at $1.76 on Friday. The business has a fifty day simple moving average of $2.93 and a two-hundred day simple moving average of $3.77. Geron has a 1 year low of $1.46 and a 1 year high of $5.34. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74.

Institutional Trading of Geron

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GERN. Alternative Investment Advisors LLC. boosted its holdings in shares of Geron by 13.3% during the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 2,612 shares in the last quarter. Rovin Capital UT ADV boosted its holdings in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 3,660 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,094 shares in the last quarter. Xponance Inc. lifted its holdings in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,829 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in shares of Geron by 68.4% in the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 7,429 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.